The following transcript has been edited for clarity:

Hi, I’m Diana V. Do, MD. Welcome to the Retinal Physician video channel. Today I’m joined by a world expert in GLP1 agonists, Aleksandra V. Rachitskaya, MD. Tell us, what are the key messages a retina specialist needs to know about the interplay of GLP1 and diabetic eye disease.

Dr. Rachitskaya: I think there is so much interest when it comes to GLP1-RA and to your point it's diabetic retinopathy, but we're actually going beyond diabetic retinopathy and here at Academy and in publications recently people are looking at glaucoma and NAION and interestingly at age-related macular degeneration (AMD). So there's a lot of interest. I think with diabetic retinopathy in particular, the take-home message is that rapid decrease in hemoglobin A1C probably drives some of the changes, and then stabilizes. But the question is, are there other mechanism of actions that we see in these medications, in GLP1-RAs? Do they play potentially different roles in other diseases of the eye? So it’s very exciting.

Dr. Do: Wonderful! Thank you again for leading the charge on that research and thank you for joining Retinal Physician. RP